Effects of chronic intraventricular administration of angiotensin II on drinking behavior and blood pressure

Prolonged effects of intracerebroventricular angiotensin II on drinking, eating and locomotor behavior in mice

The effects of centrally administered Angiotensin II (Ang II) on water and food intake in rodent models are well known. However, most studies have focused on the acute effects of intracranial Ang II. In the current study, we evaluated the effects of intracerebroventricular Ang II on food and water intake as well as locomotor activity over the entire dark phase of the murine diurnal cycle. Consistent with the previous reports, centrally administered Ang II rapidly stimulated water intake over the initial 1-hour period following treatment. However, this acute increase was immediately followed by a marked reduction in water intake resulting in decreased cumulative water intake approximately 7h after Ang II treatment. Pretreating animals with an Ang II type 1 receptor blocker, Losartan, completely antagonized the acute effect of Ang II and abolished initial water intake. In contrast, application of an Ang II type 2 receptor blocker, PD123319, abrogated the prolonged inhibitory effect of Ang II on drinking behavior and partially suppressed the initial increases in water intake. The suppressive effects of Ang II on cumulative food intake and spontaneous physical activity were also evident throughout the entire dark phase of diurnal cycle. These experiments are the first to suggest that the stimulatory effect of central Ang II treatment on water consumption is very temporary and that it causes a sustained suppressive effect on voluntary locomotion and food intake behavior in mice.

Angiotensin II and III suppress food intake via angiotensin AT(2) receptor and prostaglandin EP(4) receptor in mice

Intracerebroventricularly administered angiotensin (Ang) II and III dose-dependently suppressed food intake in mice and their anorexigenic activities were inhibited by AT(2) receptor-selective antagonist. Ang II did not suppress food intake in AT(2) receptor-knockout mice, while it did significantly in wild-type and AT(1) receptor-knockout mice. The suppression of food intake in AT(1) receptor-knockout mice was smaller than that in wild-type. The anorexigenic activities of Ang II and III were also blocked by a selective antagonist for prostaglandin EP(4) receptor. Taken together, centrally administered Ang II and III may decrease food intake through AT(2) receptor with partial involvement of AT(1) receptor, followed by EP(4) receptor activation, which is a novel pathway regulating food intake.

Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat

Advanced heart failure is characterized by increased activation of the renin-angiotensin system and the development of cachexia. Angiotensin II (Ang II) has been proposed as a lipid metabolism regulator. The effects of exogenous Ang II (osmotic minipump, 525 ng/kg/min for 12 d) on interstitial sc glycerol and norepinephrine levels, indexes of lipolysis, and sympathetic activation, respectively, were measured in Sprague Dawley rats by consecutive microdialysis performed in vivo in white adipose tissue. Higher sustained interstitial glycerol and norepinephrine levels were found after 7 and 12 d of Ang II infusion. Triglyceride to DNA content ratio and adipocyte diameter were reduced in sc and visceral (retroperitoneal and epididymal) fat tissues of Ang II-infused rats, whose body weight was lower and blood pressure higher. Losartan, an Ang II receptor 1 blocker, and carvedilol, an alpha1-nonselective-beta1,2,3-adrenergic blocker, but not doxazosin, an alpha1-selective-adrenergic blocker, lowered glycerol and norepinephrine levels, preventing lipolysis and weight loss. Our results indicate that Ang II stimulates lipolysis in sc and visceral adipocytes by sympathetic activation and beta-adrenergic-receptor stimulation. Nonselective-beta-adrenergic and Ang II-receptor1 blockade markedly attenuated the rise of norepinephrine, preventing catabolic effects. The metabolic benefits of carvedilol and losartan, in addition to recognized protective cardiovascular effects, may be relevant in cachectic patients with advanced heart failure.

Central angiotensin II AT1 receptors mediate fetal swallowing and pressor responses in the near-term ovine fetus

Swallowed volumes in the fetus are greater than adult values (per body weight) and serve to regulate amniotic fluid volume. Central ANG II stimulates swallowing, and nonspecific ANG II receptor antagonists inhibit both spontaneous and ANG II-stimulated swallowing. In the adult rat, AT1 receptors mediate both stimulated drinking and pressor activities, while the role of AT2 receptors is controversial. As fetal brain contains increased ANG II receptors compared with the adult brain, we sought to investigate the role of both AT1 and AT2 receptors in mediating fetal swallowing and pressor activities. Five pregnant ewes with singleton fetuses (130 +/- 1 days) were prepared with fetal vascular and lateral ventricle (LV) catheters and electrocorticogram and esophageal electromyogram electrodes and received three studies over 5 days. On day 1 (ANG II), following a 2-h basal period, 1 ml artificial cerebrospinal fluid (aCSF) was injected in the LV. At time 4 h, ANG II (6.4 microg) was injected in the LV, and the fetus was monitored for a final 2 h. On day 3, AT1 receptor blocker (losartan 0.5 mg) was administered at 2 h, and ANG II plus losartan was administered at 4 h. On day 5, AT2 receptor blocker (PD-123319; 0.8 mg was administered at 2 h and ANG II plus PD-123319 at 4 h. In the ANG II study, LV injection of ANG II significantly increased fetal swallowing (0.9 +/- 0.1 to 1.4 +/- 0.1 swallows/min; P < 0.05). In the losartan study, basal fetal swallowing significantly decreased in response to blockade of AT1 receptors (0.9 +/- 0.1 to 0.4 +/- 0.1 swallows/min; P < 0.05), while central injection of ANG II in the presence of AT1 receptor antagonism did not increase fetal swallowing (0.6 +/- 0.1 swallows/min). In the PD-123319 study, basal fetal swallowing did not change in response to blockade of AT2 receptor (0.9 +/- 0.1 swallows/min), while central injection of ANG II in the presence of AT2 blockade significantly increased fetal swallowing (1.5 +/- 0.1 swallows/min; P < 0.05). ANG II caused significant pressor responses in the control and PD-123319 studies but no pressor response in the presence of AT1 blockade. These data demonstrate that in the near-term ovine fetus, AT1 receptor but not AT2 receptors accessible via CSF contribute to dipsogenic and pressor responses.

Effect of central angiotensin II on body weight gain in young rats

Systemic infusion of ANG II decreases body weight and food intake and increases energy expenditure. We recently reported that young rats receiving a 1-week intracerebroventricular (i.c.v.) infusion of angiotensin II (ANG II) exhibited decreased body weight compared to control. The aim of the present investigation was to determine if chronic i.c.v. infusion of ANG II also decreases food intake and increases energy expenditure. Young rats were infused with i.c.v. 0.9% saline or ANG II (16.7 or 4.2 ng/min) for at least 10 days and body weight and food intake were monitored daily. Pair-fed rats had the same daily food intake as the ANG II-infused rats. The i.c.v. ANG II decreased body weight gain and food intake. The decrease in weight gain was greater than in the pair-fed groups. The expression of mRNA for uncoupling protein-1 (UCP-1) in BAT was increased significantly in the ANG II-infused rats compared to the pair-fed animals. Subcutaneous infusion of ANG II at the same doses used for i.c.v. infusion had no effect on body weight or food intake. The expression of CRH mRNA in the paraventricular nucleus was not increased in the ANG II-infused rats. These data are consistent with the idea that i.c.v. ANG II decreases body weight gain in young rats, in part, by decreasing food intake and, in part, by increasing thermogenesis (although via a CRH-independent mechanism). This central effect of ANG II may contribute to or complement the effect of peripheral ANG II on body weight.

Central AT1 and AT2 receptors mediate chronic intracerebroventricular angiotensin II-induced drinking in rats fed high sodium chloride diet from weaning

Intracerebroventricular (ICV) angiotensin (AIl) administration stimulates central AII receptors to induce water consumption in rats. The aim of this study was to determine the role of brain AT1 and AT2 receptors in mediating chronic ICV AII-induced drinking in rats raised on normal or high sodium chloride diets from weaning. Rats were weaned at 21 days of age and placed on normal or high sodium chloride diet for 10-12 weeks. At adulthood, the animals were instrumented with brain lateral ventricular cannulas and femoral arterial catheters. Low dose chronic central AII infusion (20 ng min(-1)) significantly (P < 0.05) increased water intake in both groups of rats when compared with their respective controls of 24 h artificial cerebrospinal fluid infusions. In a separate group of high sodium fed rats, coinfusion of AII with the AT1 receptor antagonist, losartan (0.25 microg min(-1)) or the AT2 receptor blocker, PD 123319 (0.50 microg min(-1)) blocked chronic ICV AII-induced drinking. Upon reinfusion of AII water intake increased above control. Following the cessation of AII infusions, water intake returned to values not significantly different from control (P > 0.05). In contrast, in the normal sodium fed rats losartan, but not PD 123319, blocked the AII-mediated water intake. The data demonstrate that in high sodium chloride fed rats AII stimulates both central AT1 and AT2 receptors to induce drinking, while in the normal sodium chloride fed rats the peptide activates the drinking response primarily by stimulation of central AT1 receptors.

Intracerebroventricular infusion of angiotensin II increases water and ethanol intake in rats

The influence of prolonged ingestion of ethanol on stimulation of water or ethanol intake by intracerebroventricular infusion of ANG II was evaluated in rats. Animals were maintained for 5-6 mo with either 10% ethanol solution or water as their only source of fluid. In both groups of rats, infusion of ANG II caused a large increase in water intake (7-fold) and a lesser increase in 10% ethanol intake (2-fold). The effect of ANG II on the volume of ethanol solution ingested, however, was inversely related to the concentration of the ethanol solution. As the concentration of ethanol solution was decreased, frequency and duration of drinking bouts increased. The intake of sweetened 10% ethanol solution or commercially produced wine during infusion of ANG II was similar to the intake of 10% ethanol and not related to taste preference. In conclusion, chronic consumption of ethanol solution did not appear to adversely effect ANG II stimulation of water intake. The intake of ethanol solution during infusion of ANG II was inhibited by a direct effect of ingested ethanol and/or by indirect effect from metabolized ethanol.

The effects of central and peripheral angiotensin on hypertension and nociception in rats

Spontaneously hypertensive rats (SHRs) rats have been reported to have decreased sensitivity to pain, but as yet a mechanism has not been identified. This study investigated the effects of subcutaneous and intracerebroventricular (ICV) infusions of angiotensin II on blood pressure, locomotor activity, and tailflick and hot plate latencies in the Wistar-Kyoto (WKY) and outbred Wistar rat. Peripheral but not central administration of angiotensin II (567 micrograms/kg/day) increased hot plate latencies in WKY and Wistar rats to a level equivalent to that observed in the SHR. Peripheral administration of norepinephrine (50 and 100 mg/kg/day) to WKYs increased blood pressure but had no effect on hotplate latency. ICV administration of losartan (1 & 3 mg/kg/day) to SHRs had no effect on blood pressure or nociception. The results indicate that angiotensin II has a role in the altered pain perception observed in the SHR and that its site of action is peripheral.

Continuous and direct infusion of drug solutions in the brain of awake animals: implementation, strengths and pitfalls

One of the best strategies for understanding an animal's behavior is to study the function of the brain by experimentally modifying brain chemistry temporarily or on a long-term basis. This can be achieved by direct manipulation of neurochemistry of a targeted brain area with various drugs whose in vitro specificity and sensitivity are known. We assume that an animal's behavior is primarily controlled by the integrated performance of neural networks, rather than the action of a "superstar" single neuron which has narrowly tuned selectivity, in a specified brain region. Therefore, the former must be regulated by a large number of combinations of various transmitter/modulator receptors, hormones, growth factors, and other biochemically identifiable and yet unidentified substances. Under certain conditions, the activation of receptor-bound second messenger systems is thought to cause the enhanced expression of particular genes. Given the wide possibilities in manipulating brain chemistry, which may otherwise result in a variety of consequences, it is crucial to have a dependable means of sustaining the steady-state action of a drug for a sufficiently long time period at a targeted area in the brain of behaving animals. In most cases the continuous application of a drug is necessary to counteract its secondary mitigating effect, which is set in action through negative feedback loops and which in effect reduces the primary action of the drug in use. We have developed a technique to answer this need, using the Alzet osmotic minipump as the source of the continuous infusion force. A drug solution is continuously and directly infused, guided through a chronically implanted cannula, into a targeted area in the brain of behaving animals. The consequences of such an infusion are assessed, during as well as after the infusion, using various types of measurements in behavior, biochemistry, neurophysiology, pharmacology and morphology. The method has been successfully applied, for example, to the study of developmentally regulated neural plasticity in cat visual cortex. A few preconditions should be satisfied for the method to be properly applied to the brains of live animals. Those are: (1) manufacturing a suitable guide system, i.e., cannula-minipump assembly, for the infusion solution; (2) stereotaxic implantation of a cannula-minipump assembly into a selected brain region; and (3) estimating the concentration gradient of the continuously infused solution. This is crucial to assess the specificity and sensitivity of a drug for its assumed effects in vivo.

Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism

The renin-angiotensin system regulates normal cardiovascular homeostasis and is activated in certain forms of hypertension and in heart failure. Angiotensin II has multiple physiological effects and we have shown recently that its growth-promoting effects on vascular smooth muscle require autocrine activation of the IGF I receptor. To study the effect of angiotensin II on circulating IGF I, we infused rats with 500 ng/kg/min angiotensin II for up to 14 d. Angiotensin II markedly reduced plasma IGF I levels (56 and 41% decrease at 1 and 2 wk, respectively) and IGF binding protein-3 levels, and increased IGF binding protein-2 levels, a pattern suggestive of dietary restriction. Compared with sham, angiotensin II-infused hypertensive rats lost 18-26% of body weight by 1 wk, and pair-feeding experiments indicated that 74% of this loss was attributable to a reduction in food intake. The vasodilator hydralazine and the AT1 receptor antagonist losartan had comparable effects to reverse angiotensin II-induced hypertension, but only losartan blocked the changes in body weight and in circulating IGF I and its binding proteins produced by angiotensin II. Moreover, in Dahl rats that were hypertensive in response to a high-salt diet, none of these changes occurred. Thus, angiotensin II produces weight loss through a pressor-independent mechanism that includes a marked anorexigenic effect and an additional (likely metabolic) effect. These findings have profound implications for understanding the pathophysiology of conditions, such as congestive heart failure, in which the renin-angiotensin system is activated.

The lateral preoptic area plays a dual role in the regulation of thirst in the rat

Electrolyte lesion and ibotenic acid lesion of the lateral preoptic area (LPO) of the rat were used to study the participation of this area in drinking behavior. Drinking was induced by cellular dehydration, hypovolemia, hypotension, and water deprivation. The animals with electrolytic lesion of the LPO showed a significant reduction in water intake in response to cellular dehydration, hypotension, and deprivation. The animals with ibotenic acid lesion of the LPO increased the water consumption produced by subcutaneous (SC) injection of hypertonic saline. The amount of water intake after SC injection of polyethyleneglycol (PEG) or isoprenaline was similar in control and ibotenic acid-lesioned animals. The rats with ibotenic acid lesion of the LPO drank significantly more water than control animals. Fibers of passage may also influence the drinking response, and the LPO may have osmosensitive receptors that facilitate water intake in connection with other areas of the central nervous system (CNS) that are implicated in drinking behavior.

Salt preference elicited by chronic intracerebroventricular angiotensin II

1. Much more water was consumed than either 0.9% or 2.7% saline in response to various dipsogenic stimuli in untreated normal replete rats when they had free access to water, 0.9% and 2.7% saline. On the other hand, the rats drank more 0.9% saline than water and 2.7% saline when each solution is the sole drinking fluid offered. 2. A marked increase in preference for 0.9% saline was observed during the chronic i.c.v. injection of angiotensin II at a dose of 25 ng/hr for 7 consecutive days in the three bottle choice test. After the cessation of angiotensin II infusion, most rats (45 out of 50 rats) returned to drink much more water than 0.9% and 2.7% saline, similar to the drinking pattern of the 0.9% saline-treated control rats. However, some rats (5 out of 50 rats) still preferred 0.9% saline and this persisted for up to 3 months although these rats did not show a hypertensive state and an increase of plasma renin activity.

Brain angiotensin II and baroreceptor reflex function in spontaneously hypertensive rats

We examined whether the increase in baroreceptor reflex function previously reported in lifetime - captopril-treated spontaneously hypertensive rats (SHR) was due to an inhibition of brain angiotensin II mechanisms. Pregnant and lactating SHR were given oral captopril (100 mg/kg/day). After weaning, pups were maintained on captopril (50 mg/kg/day) until the study (19-21 weeks). Control rats received tap water. One week before study captopril-treated and control SHR were given an intracerebroventricular infusion of angiotensin II (7.5 ng/hr, osmotic pump) or vehicle (artificial cerebrospinal fluid). Baroreceptor reflex control of heart rate was assessed by the slope of the relation between the change in mean arterial pressure (mm Hg) versus the change in pulse interval (msec beat-1). Arterial pressure was raised or lowered by intravenous bolus injections of phenylephrine or nitroprusside, respectively. Central infusion of angiotensin II had no significant effect on mean arterial pressure in captopril or control SHR (captopril-angiotensin II 125 +/- 4 vs. captopril-vehicle 121 +/- 2; control-angiotensin II 169 +/- 5 vs. control-vehicle 173 +/- 7 mm Hg), but it produced a significant rise in basal heart rate (captopril-angiotensin II 371 +/- 10 vs. captopril-vehicle 323 +/- 8, p less than 0.0002; control-angiotensin II 338 +/- 7 vs. control-vehicle 312 +/- 8 beats/min, p less than 0.0183) and in daily water intake (captopril-angiotensin II 20.7 +/- 2.2 vs. captopril-vehicle 9.8 +/- 0.7, p less than 0.0426; control-angiotensin II 33.1 +/- 3.8 vs. control-vehicle 9.0 +/- 0.6 ml/100 g body wt, p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of increased circulating angiotensin II (AII) on fluid exchange and binding of AII in the brain

Previous studies have shown that elevated levels of circulating angiotensin II (AII) can influence the binding capacity of this peptide for its receptors in peripheral tissues, but the effect of increased circulating levels of AII on its receptors in the brain has not been well-defined. In the present study, the effect of chronic subcutaneous infusions of AII on: (1) the binding of AII to neuronal membranes from the diencephalon (hypothalamus, thalamus and septum) (HTS) of the brain; (b) water intake and urine output, (c) blood pressure, and (d) their interrelationships was evaluated in rats. Significant increases in daily water intake and urine output accompanied chronic infusions of AII at a rate of 125 ng/kg/min. Both blood pressure and the concentration of aldosterone in plasma were also elevated in these rats. The acute dipsogenic response to either central (10 ng) or peripheral (100 micrograms/kg, SC) administration of AII was also tested both in controls and in rats receiving chronic infusions of AII at a rate of either 40 or 125 ng/kg/min, and no differences were observed. Analysis of the HTS region of the brain revealed a significant increase in the specific binding of AII in AII-infused rats compared to controls. Scatchard analysis of the specific binding of AII to its receptors in the HTS of rats treated with 40 ng AII/kg/min for 6 days revealed a significant increase in the number of binding sites for AII compared to controls (Bmax 12.13 vs. 8.79 fmol/mg protein), but no change in binding affinity (Kd).(ABSTRACT TRUNCATED AT 250 WORDS)

Rat brain angiotensin II receptors: effects of intracerebroventricular angiotensin II infusion

Angiotensin II (Ang II) was infused into a lateral cerebral ventricle of male Sprague-Dawley rats and its effects on blood pressure, water balance and specific [125I]Ang II binding to brain and adrenal tissues were studied. The infusion was maintained at a rate of 500 ng/microliter/h for 6 days using subcutaneously implanted osmotic minipumps. A control group was infused intracerebroventricularly (i.c.v.) with 0.9% saline at a rate of 1 microliter/h for 6 days. Angiotensin II treated rats showed a four-fold increase in water intake and urine volume and a moderate increase in blood pressure; these effects were not observed in rats given saline i.c.v. There was no significant difference in [125I]Ang II binding site density or binding affinity in either the hypothalamus-thalamus-septum-midbrain (HTSM) or the brainstem between Ang II-treated and saline-treated groups. In addition, [125I]Ang II binding sites in the adrenals were also unaffected by i.c.v. infusion of Ang II. The results suggest that brain Ang II receptors are unresponsive to increased Ang II levels in cerebrospinal fluid.

Interaction between areas of the central nervous system in the control of water intake and arterial pressure in rats

Water intake induced by injection of 0.2 M-NaCl into the lateral preoptic area was increased by the injection of angiotensin II into the subfornical organ of rats. The injection of hypertonic saline solution into the subfornical organ increased water intake. However, the increase was lower than when the solution was injected into the lateral preoptic area. The injection of 4 micrograms angiotensin II into the lateral preoptic area further augmented this effect. Injection of angiotensin II into the subfornical organ caused a rise in blood pressure which preceded the thirst-inducing effect. The injection of 0.2 M-NaCl into the subfornical organ caused no changes in blood pressure, whereas the injection of angiotensin II into the lateral preoptic area caused some increase. Dehydration of the lateral preoptic area by means of 0.2 M-NaCl in combination with intravenous infusion of angiotensin II caused a summation of effects in terms of the water intake, without changing cardiovascular alterations induced by the infusion of angiotensin II. A summation of effects in the water intake, but not in blood pressure, was also observed when 0.5 M-NaCl was infused intravenously in combination with the injection of angiotensin II into subfornical organ and into the lateral preoptic area. The results indicate that there are interactions between the subfornical organ and lateral preoptic area in the regulation of cardiovascular and thirst mechanisms.

Two inhibitors of angiotensin-converting enzyme, enalapril and captopril, increase salt appetite of rats

Male rats were orally administered an inhibitor of angiotensin-converting enzyme (ACE), N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-1-ala-1-pro maleate (enalapril, MK-0421) at dosage levels of 10, 30, and 90 mg/kg X d. After 2-6 wk of dosing, the rats receiving 30 and 90 mg/kg X d produced large numbers of seminal plugs and had lacerated penises due to licking in an attempt to recover urine. Providing 0.9% saline as the source of drinking water prevented this behavior and subsequent lesions. There were no adverse effects on reproductive performance. A subsequent study showed that enalapril at 5 mg/kg X d po and captopril (another ACE inhibitor) at 25 mg/kg X d po increased NaCl intake in rats. Our results with captopril confirm those of Fregly (1980) and Evered and Robinson (1983) and show that both converting-enzyme inhibitors (enalapril and captopril) increase salt appetite in rats.

Cerebrospinal fluid pressure during cerebroventricular infusion of angiotensin and vasopressin

Rationale exists for suspecting that angiotensin (Ang) and arginine vasopressin (AVP) given by the intracerebroventricular (IVT) route can affect cerebrospinal fluid (CSF) pressure. This hypothesis was tested in conscious, unrestrained adult male Sprague-Dawley rats with IVT and left carotid arterial catheters. The rats were infused (IVT) for 30 min with artificial CSF followed by 30 additional minutes with CSF, Ang, (0.6 micrograms/h) AVP (5 or 50 ng/h), or AVP (5 or 50 ng/h) + Ang, (0.6 micrograms/h). Angiotensin evoked a central hypertensive effect (+ 16 mm Hg) and increased CSF pressure from 10 to 16 cm H2O (P less than 0.05). Neither dose of AVP affected blood or CSF pressures. The AVP (5 ng/h) prevented Ang-induced changes in blood and CSF pressures and AVP (50 ng/h) blocked only the Ang-induced rise in CSF pressure. These results raise the possibility that angiotensin and vasopressin participate in the regulation of CSF pressure.

Infusions of chemicals into the brain and the development of sustained elevations of blood pressure in the rat

Osmotic minipumps were used to infuse carbachol chloride (1.23 micrograms/hr), echothiophate iodide (0.5 microgram/hr), histamine dihydrochloride (10 micrograms/hr), prostaglandin E2 (1.0 microgram/hr) and thyrotropin-releasing hormone (0.5 and 5.0 micrograms/hr) solutions into the cerebral ventricles of unanesthetized rats and blood pressure was measured by the tail-cuff method. Histamine dihydrochloride, prostaglandin E2 and thyrotropin-releasing hormone produced an initial rise in blood pressure, but were not effective in producing sustained elevations in blood pressure. Carbachol infusions elevated blood pressure throughout the 7-day infusion period when results were compared to saline-infused animals. Infusions of echothiophate iodide, an anticholinesterase agent, produced an initial rise in blood pressure but these pressor effects were not sustained. In animals infused with echothiophate for 7 days, the pressor response to a challenge dose of echothiophate was diminished.

Studies of the functional significance of angiotensin II receptors in the rat olfactory bulb: evidence for alterations in normal fluid intake

The effects of continuous infusion of angiotensin II (ANG II, 1 microgram hr-1) into the olfactory bulb (O.B.) were studied on rats with chronically indwelling intracerebral cannulae. Chronic infusion (ALZA minipump system) of ANG II into the O.B. elicited a moderate dipsogenesis as compared to saline infused animals. The increased drinking occurred only during the dark phase (6 pm - 6 am) and appeared to be associated with food intake, which also occurred during this time. Removal of the food or disconnection of the minipump reduced water consumption to comparable levels in both groups. Acute injection of ANG II (250 ng) into the O.B. failed to elicit drinking. Since the olfactory bulb has a high concentration of ANG II receptors, these experiments suggest that ANG II may interact with the O.B. to facilitate the drinking associated with food intake.

The osmotic pump: novel research tool for optimizing drug regimens

Evaluation and selection of drugs, and determination of the optimal regimen, for controlled-release pharmaceutical products necessitate the reassessment of the pharmacology of drugs delivered at controlled rates. We have developed osmotic pumps for this purpose. These pumps, 1- and 2-week duration implants for animal studies, and 12- and 24-hour forms for oral and rectal administration in clinical studies, provide precise, accurate control over rate and duration of systemic or local drug delivery.